Bio-Rad (BIO) Q2 2024: Process Chromatography Declines 16%, Margin Expansion Offsets Life Science Drag
Bio-Rad delivered Q2 revenue in line with expectations, but persistent weakness in process chromatography and biopharma segments forced a full-year outlook cut. Margin expansion was driven by disciplined cost controls and improved product mix, partially insulating results from top-line softness. Investors face a slower recovery trajectory for life sciences, as management signals a more measured pace of market normalization into 2025.
Summary
- Margin Expansion Outpaces Revenue Drag: Cost discipline and mix drove upside to gross margin despite sales pressure.
- Life Science Recovery Deferred: Process chromatography and biopharma demand remain subdued, pushing growth expectations to 2025.
- Capital Deployment Shifts: Opportunistic repurchases ramp up as M&A and asset monetization remain on hold.
Business Overview
Bio-Rad Laboratories is a global provider of products for the life science research and clinical diagnostics markets. The company generates revenue through two major segments: Life Science (instrumentation, reagents, digital PCR, process chromatography for research and biopharma production) and Clinical Diagnostics (immunohematology, quality controls, and blood typing products for healthcare labs). Revenue is diversified globally, with significant exposure to biopharma, biotech, academic research, and clinical laboratory customers.
Performance Analysis
Bio-Rad’s Q2 results reflected the ongoing bifurcation between its stable Clinical Diagnostics business and its challenged Life Science segment. Clinical Diagnostics delivered steady, broad-based growth across all regions, with strength in immunohematology and blood typing offsetting prior supply chain disruptions. In contrast, Life Science sales fell sharply, led by a 16.5% reported decline (15.9% currency-neutral) as process chromatography and instrumentation demand remained weak, particularly among large biopharma clients still working through excess inventory.
Gross margin rose to 55.6% (GAAP), up from 53.2% last year, as cost controls, productivity initiatives, and favorable product mix offset lower volumes. Operating margin also improved, with SG&A and R&D spend tightly managed. However, the company posted a net loss driven by a non-cash loss on equity securities, unrelated to core operations. Free cash flow was $55 million, down from $63 million YoY, reflecting higher strategic inventory but stable cash generation from operations.
- Diagnostics Growth Broadens: Clinical Diagnostics now accounts for over 60% of revenue, with normalized growth projected through year-end.
- Life Science Core Stabilizes: Excluding process chromatography, core Life Science revenue declined 11.6% YoY, but sequential trends improved mid-single digits.
- Margin Leverage from Cost Actions: 90% of gross margin improvement attributed to cost control, mix, and logistics efficiency, not volume recovery.
Process chromatography remains the largest drag, driven by destocking at a handful of large customers, with no recovery expected until 2025. Digital PCR consumables held up well, but instrumentation sales remain under pressure. The company’s new product launches are early-stage and not yet contributing materially to revenue.
Executive Commentary
"While we have seen some positive signs with the improved biotech funding, we are continuing to see constraints in biotech biopharma spending globally. As such, we do think it's prudent to revise our full year 2024 financial outlook to better reflect what I think of as a more modest pace of market recovery than originally predicted."
Norman Schwartz, Chief Executive Officer
"Q2's strength in the gross margin specifically is associated with mix. But the other part of it is really sustained improvements based on our cost initiatives and efficiency improvements and things like logistics costs that we've been very proactively managing. ... We do expect that that's a sustained into the second half of the year and beyond."
Rubalak Raju, Chief Financial Officer
Strategic Positioning
1. Life Science Recovery Delayed
Process chromatography, high-value purification products for bioproduction, continues to face severe destocking among a small set of large customers. Management now expects no meaningful recovery in this area until 2025, with ongoing headwinds in both China and developed markets. Core Life Science, excluding process chromatography, is stabilizing but remains below prior-year levels due to softness in biopharma and academic funding.
2. Diagnostics as Foundation
Clinical Diagnostics, routine lab testing and blood products, is providing ballast for Bio-Rad’s results. Growth is broad-based, with normalization of supply chains and steady demand in all regions. The company continues to invest in supporting core platforms and expanding into new molecular diagnostic segments, positioning this division for consistent growth.
3. Cost Discipline and Productivity
Margin expansion is being driven by rigorous cost controls, improved supply chain management, and favorable product mix, not top-line growth. Management has proactively managed SG&A and R&D expenses, with headcount and discretionary spending under scrutiny. These efforts are expected to provide further leverage when end markets recover.
4. Capital Allocation and Buybacks
Bio-Rad accelerated share repurchases, buying back $196 million in Q2 and July, and increasing authorization by $500 million. Leadership views the stock as undervalued, but remains cautious on large-scale buybacks relative to balance sheet size. M&A remains under consideration, but only for strategic, appropriately valued assets that fit the product roadmap.
5. Innovation Pipeline and New Product Launches
New platforms, including the CHEMI.GO imaging system and a cost-effective single-cell sample prep solution, are in early launch phases. The QX continuum, a low-end digital PCR instrument, is slated for Q4 introduction, targeting market segments where competitors are more established. An acquisition of novel droplet technology for antibody and T-cell receptor discovery is expected to close in 2024, with commercial impact in two to three years.
Key Considerations
Bio-Rad’s Q2 underscores a business in transition, balancing near-term headwinds against margin gains and longer-term innovation bets. The company’s ability to offset top-line weakness with cost actions is notable, but the path to growth in Life Science remains uncertain, hinging on inventory normalization and funding improvements.
Key Considerations:
- Diagnostics Momentum Holds: Resilient diagnostics growth offers stability, but is insufficient to offset Life Science drag alone.
- Process Chromatography Drag: Destocking at large customers is deeper and more prolonged than peers, with recovery visibility limited until 2025.
- Inventory Management Challenge: Elevated inventory levels (over 30% of sales) reflect both strategic stockpiling and operational inefficiency, with management targeting improved turns.
- Capital Allocation Flexibility: Share repurchases ramped up, but management remains disciplined, not prioritizing buybacks over M&A or asset monetization.
- Innovation Pipeline Slow to Impact: New product launches are progressing, but are not expected to contribute materially in 2024, with focus on building market position for future years.
Risks
Bio-Rad faces several material risks: prolonged weakness in biopharma demand, especially in process chromatography, could extend beyond current expectations. China remains a wild card, with new stimulus unlikely to provide near-term relief. Elevated inventory levels could constrain future cash flow if not addressed. Competitive dynamics in digital PCR and single-cell markets may intensify as new products launch. Execution risk around cost control and new product commercialization also bears watching.
Forward Outlook
For Q3 and the second half of 2024, Bio-Rad guided to:
- Approximately 2% YoY currency-neutral revenue growth in H2, following a 7.5% decline in H1.
- Life Science group revenue down 10% to 12% for the year (4% decline excluding process chromatography), with low double-digit sequential growth expected in H2 over H1.
- Diagnostics group revenue up 3% to 3.5% for the year, with continued normalized growth.
For full-year 2024, management lowered guidance:
- Currency-neutral revenue to decline 2.5% to 4% (prior: up 1% to 2.5%).
- Non-GAAP gross margin raised to 54.5% to 55% (prior: 54% to 54.5%).
- Non-GAAP operating margin cut to 12% to 13% (prior: 13.5% to 14%).
- Adjusted EBITDA margin to 18% to 19% (prior: 19.5% to 20%).
Management highlighted:
- Process chromatography recovery deferred to 2025, with destocking expected to persist through year-end.
- Diagnostics growth and cost actions supporting margins, but volume recovery is the key swing factor.
Takeaways
Bio-Rad’s Q2 results reflect a business in margin defense mode, with diagnostics strength and cost actions partially shielding the company from biopharma and process chromatography headwinds. The path to growth in Life Science is slower than peers, with recovery in key segments pushed into next year.
- Diagnostics Offsets, But Cannot Fully Compensate: Stable diagnostics growth provides a foundation, but Life Science drag is too large to overcome in the near term.
- Cost Actions Buy Time, Not Growth: Margin gains are real, but sustainable top-line growth requires macro and customer normalization, especially in process chromatography and biopharma.
- Watch for Inventory Reduction and New Product Uptake: Investors should monitor inventory turns and the ramp of new platforms as indicators of operational and commercial execution into 2025.
Conclusion
Bio-Rad’s Q2 demonstrates disciplined execution and margin protection amid persistent Life Science headwinds. While diagnostics growth and cost controls provide near-term stability, the company’s long-term trajectory depends on recovery in process chromatography and new product adoption. Investors should expect a measured, multi-quarter normalization rather than a rapid rebound.
Industry Read-Through
Bio-Rad’s results underscore the uneven recovery in life science tools, with process chromatography and biopharma capital spending remaining weak across the sector. Destocking and soft funding environments, especially in China and academic markets, are likely to weigh on peers with similar exposure. Diagnostics businesses with recurring revenue streams are proving more resilient, while instrumentation-heavy models face ongoing headwinds. The slow pace of market recovery and persistent inventory challenges signal that normalization across bioprocessing and research end markets is likely to be a 2025 story, not a 2024 one.